Q1 2026 BULLSEYE CHARTS
The Psychedelic Drug Development Pipeline
UBC partners with biopharma to modernize evidence development and patient access for emerging therapies. By integrating real-world data, risk management, and deep patient insights, UBC helps sponsors demonstrate long-term value, meet regulatory expectations, and support safe, scalable access.
This resource is supported by
UBC partners with biopharma to modernize evidence development and patient access for emerging therapies. By integrating real-world data, risk management, and deep patient insights, UBC helps sponsors demonstrate long-term value, meet regulatory expectations, and support safe, scalable access.
Q1 2026 Psychedelic Drug Development Bullseye Chart
Download a PDF Copy of the Charts
Access a high-resolution PDF of the bullseye charts by entering your email. By doing so, you are also opting in to our free newsletter.
By Indication Grouping
In addition to our full pipeline Bullseye Chart, above, we have also produce a Bullseye that focuses on Phase 2+ assets, grouped by broad indication.
Download a PDF Copy of the Charts
If you would like to receive a high-resolution PDF of the bullseye charts, please enter your email below. By doing so, you are also opting in to our free newsletter.
Pα+ delivers the psychedelic drug development intelligence that serious stakeholders rely on.
Get in-depth coverage of psychedelic drug development, policy and regulation, as well as exclusive interviews and data. With expert analysis and curated insights, Pα+ keeps you informed on the decisions shaping the future of psychedelics. Subscribe today, or get in touch to discuss team plans.
Ready to subscribe to Pα+? Choose a monthly or annual plan by clicking the appropriate button below.
Looking for team/group plans? Email plus@psychedelicalpha.com.
